Systemic lupus erythematosus (SLE) Market

Systemic Lupus Erythematosus Market – Overview

The global systemic lupus erythematosus market is anticipated to grow at a healthy rate during the forecast period (2021 to 2031). Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that impacts several organs and has a wide range of clinical symptoms. Although the use of corticosteroids and conventional immunosuppressive medicines has increased in recent decades, there is still unfulfilled demand for treatments with improved safety and efficacy profiles. The constant involvement of large biopharmaceutical companies in drugs that are currently in clinical trials is expected to boost the global systemic lupus erythematosus market.

Moreover, the increased prevalence of autoimmune illnesses is projected to propel the growth of the global systemic lupus erythematosus market. According to the Lupus Foundation of America, the year 2019 witnessed the growth of various firms for lupus treatment, including GSK and Aurinia Pharmaceuticals Inc. As a result, the global systemic lupus erythematosus market is likely to rise during the forecast period.

Systemic Lupus Erythematosus Market – Competitive Landscape

Prominent players in the global systemic lupus erythematosus market are GlaxoSmithKline, Mylan AG, Eli Lilly & Company, F., Sanofi SA, Hoffmann-La Roche AG, and others.

With a broad array of corticosteroids and immunosuppressants already on the market, there is an increased emphasis on collaborative drug development initiatives among global incumbent players and new entrants in the specific geographical region. Many drugs are in clinical trials, which attracts a number of funding partners and manufacturers as they seek market approvals.

Systemic Lupus Erythematosus Market – Trends and Opportunities

The incidence rate of systemic lupus erythematosus has increased, which is expected to boost the demand for systemic lupus erythematosus therapy. Moreover, the arrival of major pipeline agents and recent medication approvals is expected to boost the systemic lupus erythematosus market during the forecast period.

The advent of novel biological therapies in the development pipeline, which will increase treatment options and drug costs, is expected to propel the global systemic lupus erythematosus market. Certain highly potential medications in Phase III trials are expected to support the market growth since they may address the lupus nephritis patient population with few effective options and large unmet requirements. This aspect is likely to have a significant impact on the global systemic lupus erythematosus market, as over 50% of SLE patients experience lupus nephritis.

The growing senior population and increasing healthcare costs are anticipated to drive the global systemic lupus erythematosus market. Other major aspects such as changing lifestyle and increased awareness regarding inflammatory autoimmune illnesses and disease diagnosis and treatment are projected to positively impact the market growth rate. Moreover, advancements in medical technology, increased government financing, and growing disposable income levels are factors expected to accelerate the growth rate of the global systemic lupus erythematosus market.

Furthermore, the increase in R&D efforts, the launch of efficient medicines, and the emergence of new markets are anticipated to generate advantageous possibilities for the systemic lupus erythematosus market during the projected period. In addition, the high unfulfilled need for current treatments and advancements in healthcare technology is projected to spur market growth in the coming future.

Systemic Lupus Erythematosus Market – Regional Landscape

North America systemic lupus erythematosus market is projected to expand due to growing knowledge about the disease, improved healthcare infrastructure, and an increasing number of foundations and independent venture groups backing biopharmaceutical manufacturers.

Moreover, several companies in the North American region have launched broad awareness initiatives about the disease's diagnosis, misinformation, and treatment. This is primarily due to the numerous non-profit organizations and financial communities that support the cause. Approximately 1.5 million individuals in the United States have some type of lupus, with SLE accounting for 70% of cases, and more than 90% of those diagnosed are women in their adolescent and adult years. Furthermore, numerous favorable aspects from the government and private sectors and financing for drug development are expected to propel the regional market during the projection period.

The systemic lupus erythematosus market in Asia Pacific is expected to grow due to fast-expanding medical infrastructure, greater medical tourism, increased expenditure and improved population awareness in developing countries such as India and China.